Belleair Bluffs, Fla.-based JointPoint’s OneTrial software is designed to improve surgical outcomes in hip replacements by analyzing implant selection and positioning pre-surgical digital templating and case planning through non-invasive computer navigation. The deal is slated to close this year.
Since July 2017, Warsaw, Ind.-based DePuy has held an exclusive co-marketing agreement to market the JointPoint software platform in the U.S. When the acquisition closes, JointPoint will become a DePuy-owned component of Anterior Advantage, a solution intended to bring together DePuy’s implants and instrumentation and technologies that optimize surgical experience.
The Anterior Advantage solution includes DePuy’s Kincise surgical automated system, which is designed to automate the precision of key steps during hip replacement and is compatible with the JointPoint platform. DePuy said it plans to continue developing and broadening the JointPoint platform for additional orthopedic surgery procedures.
“JointPoint ties into our strategy to transform hip replacement and is specifically designed for use with the Anterior Approach, a tissue-sparing surgical technique which surgeons are increasingly utilizing and where we have long had an industry-leading presence,” Aaron Villaruz, VP & global platform leader for hips at DePuy Synthes, said in prepared remarks.
Shares of JNJ were up 0.3% at $129.01 apiece in early trading today.